$65.49
4.62% day before yesterday
Nasdaq, May 16, 10:20 pm CET
ISIN
US88023B1035
Symbol
TEM

Tempus AI Stock price

$65.49
+24.63 60.28% 1M
+11.43 21.14% 6M
+31.73 93.99% YTD
+28.49 77.00% 1Y
+28.49 77.00% 3Y
+28.49 77.00% 5Y
+28.49 77.00% 10Y
Nasdaq, Closing price Fri, May 16 2025
+2.89 4.62%
ISIN
US88023B1035
Symbol
TEM

Key metrics

Market capitalization $11.34b
Enterprise Value $11.98b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 14.91
P/S ratio (TTM) P/S ratio 14.11
P/B ratio (TTM) P/B ratio 34.74
Revenue growth (TTM) Revenue growth 42.93%
Revenue (TTM) Revenue $803.32m
EBIT (operating result TTM) EBIT $-700.27m
Free Cash Flow (TTM) Free Cash Flow $-211.38m
Cash position $218.79m
EPS (TTM) EPS $-4.60
P/E forward negative
P/S forward 9.10
EV/Sales forward 9.61
Short interest 15.13%
Show more

Is Tempus AI a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

Tempus AI Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Tempus AI forecast:

7x Buy
50%
7x Hold
50%

Analyst Opinions

14 Analysts have issued a Tempus AI forecast:

Buy
50%
Hold
50%

Financial data from Tempus AI

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
803 803
43% 43%
100%
- Direct Costs 358 358
34% 34%
45%
445 445
51% 51%
55%
- Selling and Administrative Expenses 762 762
189% 189%
95%
- Research and Development Expense 335 335
73% 73%
42%
-652 -652
305% 305%
-81%
- Depreciation and Amortization 48 48
40% 40%
6%
EBIT (Operating Income) EBIT -700 -700
258% 258%
-87%
Net Profit -709 -709
216% 216%
-88%

In millions USD.

Don't miss a Thing! We will send you all news about Tempus AI directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tempus AI Stock News

Neutral
Business Wire
4 days ago
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new strategic collaboration to advance Boehringer Ingelheim's growing cancer pipeline. The new, multi-year collaboration builds on foundational work the two companies have conducted in the last few years, leveraging data and A...
Neutral
GlobeNewsWire
4 days ago
The AI in Clinical Trials Market is driven by the surge in chronic diseases and increased pharma collaborations. Valued at $1.35 billion in 2024, it aims to reach $3.33 billion by 2032. North America leads due to investment in R&D and numerous trials. The AI in Clinical Trials Market is driven by the surge in chronic diseases and increased pharma collaborations. Valued at $1.35 billion in 2024,...
Neutral
Business Wire
5 days ago
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the presentation of six posters, including one oral presentation, at the 2025 annual meeting of the Professional Society for Health Economics and Outcomes Research (ISPOR), taking place May 13-16 in Montreal, Canada. Tempus resear...
More Tempus AI News

Company Profile

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Head office United States
CEO Eric Lefkofsky
Employees 2,400
Website www.tempus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today